heading · body

Earnings · CUPID · Healthcare / Consumer

Cupid — a sleepy condom exporter rebuilt by a financier-promoter

Cupid Ltd

period FY24 → FY26 (4 concalls FY24-vintage; ARs FY23–FY25) added 2026-06-09 score 6/10
earnings-call consumer healthcare condoms CUPID india

The Pulse

Cupid is one of the world’s few makers of WHO-prequalified male and female condoms — and for thirty years it was a quiet, cash-rich exporter selling into government tenders, run by a founder who openly admitted he was no capital allocator and wanted to sell. In FY24 he did: a financier-led family, the Halwasiyas, took control and rebuilt the company. They recapitalised it with a ₹385 crore warrant raise, a bonus and a 10-for-1 split, and pivoted it from an institutional condom shop into a multi-segment consumer-healthcare story — branded FMCG (deodorants, perfumes, menstrual cups) sold on Amazon and Blinkit, plus a diagnostics arm that finally turned profitable. The numbers exploded: FY26 sales nearly doubled to ₹358 crore and profit jumped to ₹108 crore, and the stock re-rated roughly eight-fold. The catch is a big one: every available earnings-call transcript predates this transformation, so we have the old founder’s voice and the new owner’s opening pitch — but not a single quarter of the new management explaining the results that drove the re-rating. And the stock now trades at 181 times earnings and 43 times book, pricing in years of flawless execution against real quality flags.

The Business

Cupid makes male and female condoms, water-based lubricant, in-vitro diagnostic (IVD) test kits, and — newly — a range of branded consumer products. Its genuine distinction is regulatory: it is the only company prequalified by the WHO and UNFPA for both male and female condoms, holds USFDA 510(k) clearance, and supplies more than 110 countries. Female condoms are a particularly scarce, high-margin niche — the old management quoted 45–50% margins on them versus 18–20% on male condoms, with effectively one qualified global competitor.

The historic model was business-to-government export: winning large institutional tenders from the WHO, UNFPA and health ministries (South Africa, Brazil, Tanzania, Government of India). Exports were ~90% of revenue. The new model is deliberately different. Under the Halwasiyas, Cupid has rebalanced to roughly half-domestic, half-export, and built two new legs: a branded FMCG business (deodorants, perfumes, petroleum jelly, menstrual cups) targeting Tier-II/III India through e-commerce and quick-commerce, which reportedly crossed ₹50 crore — over 20% of revenue — in its first year; and a diagnostics business of rapid test kits that turned profitable in FY25 and is chasing WHO/CE approvals to unlock export tenders. The thesis rests partly on a genuinely under-penetrated home market — the company cites that as few as 5% of sexually active Indian men regularly use condoms.

How Management Thinks

This is really a tale of two managements, and the contrast is the whole story. The Garg-era founder (whose voice fills the 2023 calls) was conservative to a fault: debt-free, ~95% capacity utilised, but chronically under-investing — ₹100 crore of idle cash parked in bank deposits at 6%, repeatedly dodging buyback questions, an IVD division that missed its targets for years, and crucially, no CEO and no succession plan. He was honest and plain-spoken — he admitted he “wasn’t an expert in the financial area” — but he was running a value trap, and he said so by putting his ~45% stake up for sale “for personal reasons.”

The Halwasiya regime is the opposite temperament. Aditya Halwasiya — a Fordham finance graduate, the largest individual shareholder, and a director at Tourism Finance Corp and defence-maker Apollo Micro Systems — took control via an open offer in late 2023 and reframed the company as “a fully integrated healthcare and wellness powerhouse.” This is a financier-led takeover of a founder-run manufacturer, and it shows in the moves: comfortable with dilution and acquisitions, a ₹385 crore warrant raise to fund a planned overseas acquisition (to add premium non-latex condoms) and the diagnostics push, a new Palava manufacturing plant, and an explicit ambition to triple capacity. To his credit, the “₹400 crore topline, ₹100 crore EBITDA” target he stated aloud in January 2024 has, on paper, roughly been delivered by FY26.

But the credibility read has to come with heavy asterisks, because the numbers carry real quality flags. About ₹34 crore of FY26’s ₹142 crore pre-tax profit is treasury other-income — yield on the warrant cash, not operating earnings. FY25 saw an ugly working-capital blowout (inventory days hit 450, cash conversion ballooned to 570 days, and operating cash flow went negative), only normalising in FY26. Free cash flow was negative in two of the last three years. And despite a 33% return on capital and “repeated profits,” the company pays no dividend at all — with no clear account, in the available files, of whether the cash is being redeployed or simply accumulated.

Where It’s Going

The stated direction is to keep building the consumer and diagnostics legs on top of the institutional condom base — doubling the branded segment, expanding capacity at Palava, deepening the FMCG distribution, and pushing IVD kits toward the WHO/CE approvals that open big export tenders. The female-condom franchise remains the high-margin crown jewel, and a fresh prequalification reportedly makes Cupid eligible for the entirety of South Africa’s upcoming government tender. The structural tailwinds — low domestic condom penetration, a post-pandemic healthcare push, quick-commerce reach into smaller towns — are real.

The honest tension is that this is a company mid-transformation whose most important chapter is the least documented. The growth is genuine and accelerating, but it leans on a treasury raise, a new consumer business of uncertain durability and marketing cost, and lumpy tender timing. Whether the FY25 inventory problem was a one-off or a structural feature of the new consumer model, what the ₹385 crore warrant money actually bought and at what price, and how much of the profit is organic versus financial — none of these can be answered from the files available.

The Four Checks

  1. Quality & moat (gate). Partial, and changing shape. The original moat is real but narrow: the WHO/UNFPA dual prequalification and the near-monopoly female-condom niche are genuine, defensible regulatory assets. But the new business the valuation now rests on — branded FMCG deodorants and perfumes sold on Blinkit — has no moat at all; it’s a crowded, marketing-intensive consumer category. So the durable edge sits in the legacy institutional/female-condom business, while the growth narrative is being written in a far less defensible adjacency. The gate is only half-cleared.

  2. Returns on incremental capital & runway. Headline returns are high (ROCE 33.5%, ROE 27.3%), but they need scrutiny: they’re flattered by treasury income and were earned through a period of negative free cash flow and a working-capital blowout, so the cash returns on incremental capital are far less proven than the ratios suggest. The runway for the institutional condom business is steady but slow; the consumer runway is large but unproven and capital-hungry. Verdict: high reported returns, low confidence in their durability and cash quality.

  3. Capital allocation for the stage. This is the genuinely interesting question and the available data can’t fully answer it. The new owner is clearly more active than the cash-hoarding founder — raising capital, building plants, entering new categories — which for an under-invested company is directionally right. But the moves carry risk (dilution, an as-yet-unverified overseas acquisition, an FMCG bet) and the zero dividend at 33% ROCE is unexplained. Without the FY25–FY26 concalls, the rationality of the allocation is taken largely on trust.

  4. Price. Extremely demanding — the loudest signal in the file. At 181x earnings and 43x book, after an eight-fold re-rating, the market is pricing Cupid as a flawless high-growth consumer compounder. That price assumes the FMCG and diagnostics bets work, that FY26’s growth is a durable base rather than a treasury-and-tender-aided spike, and that the working-capital and earnings-quality flags resolve benignly. The business does not yet have the track record under new management to justify that certainty, and the absence of recent management commentary makes the price even harder to defend.

Sources

Screener snapshot fetched 2026-06-09. Important data gap: the only downloadable concall transcripts were four FY24-vintage calls (Jun-2023, Aug-2023, Nov-2023, Jan-2024), which are dominated by the outgoing founder Omprakash Garg, with the incoming Halwasiya MD appearing only from November 2023 with an opening pitch. Screener lists concalls through May 2026, but those transcript links were not accessible without a screener login (no credentials configured this session). This means there is no earnings-call coverage of the entire FY25–FY26 transformation — the period when sales tripled, the consumer business launched, IVD turned profitable, and the stock re-rated. The current picture therefore rests on the snapshot (quarterly data through Mar-2026) plus the FY24 and FY25 annual-report MD&A, which clearly document the change of control and the strategic pivot. Research dumps in vault/Sources/Earnings/Cupid Ltd/.